Beam Therapeutics (BEAM) Leases (2019 - 2025)
Historic Leases for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $97.0 million.
- Beam Therapeutics' Leases fell 736.27% to $97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.0 million, marking a year-over-year decrease of 736.27%. This contributed to the annual value of $104.9 million for FY2024, which is 707.25% down from last year.
- Latest data reveals that Beam Therapeutics reported Leases of $97.0 million as of Q3 2025, which was down 736.27% from $99.6 million recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Leases peaked at $118.5 million during Q4 2022, and registered a low of $13.6 million during Q2 2022.
- Moreover, its 5-year median value for Leases was $105.5 million (2022), whereas its average is $102.7 million.
- In the last 5 years, Beam Therapeutics' Leases skyrocketed by 244271.43% in 2021 and then plummeted by 8708.64% in 2022.
- Quarter analysis of 5 years shows Beam Therapeutics' Leases stood at $102.7 million in 2021, then grew by 15.38% to $118.5 million in 2022, then fell by 4.78% to $112.8 million in 2023, then dropped by 7.07% to $104.9 million in 2024, then fell by 7.5% to $97.0 million in 2025.
- Its last three reported values are $97.0 million in Q3 2025, $99.6 million for Q2 2025, and $102.2 million during Q1 2025.